Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Juanfei Peng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0057-7411; OpenAlex author ID A5103281899. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 10

  1. Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-026-69013-y↗
  2. Hsa_circ_0007590/PTBP1 complex reprograms glucose metabolism by reducing the stability of m6A-modified PTEN mRNA in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41417-024-00786-4↗
  3. Comprehensive Analysis of PPMs in Pancreatic Adenocarcinoma Indicates the Value of PPM1K in the Tumor Microenvironment. Co-author DOI 10.3390/cancers15020474↗
  4. Retraction Note to: LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis. Co-author DOI 10.1186/s12943-022-01678-7↗
  5. METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fcell.2022.759020↗
  6. SLC45A4 promotes glycolysis and prevents AMPK/ULK1-induced autophagy in TP53 mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jgm.3364↗
  7. CircMYOF triggers progression and facilitates glycolysis via the VEGFA/PI3K/AKT axis by absorbing miR-4739 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41420-021-00759-8↗
  8. LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis. Co-author DOI 10.1186/s12943-018-0845-6↗
  9. MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro. First author DOI 10.1007/s10620-017-4472-7↗
  10. Noncoding RNAs and pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i2.801↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shineng Zhang · 8 shared papers, 2017–2024 · strength 1.21
  2. Yanyan Zhuang · 8 shared papers, 2017–2024 · strength 1.21
  3. Fengting Huang · 7 shared papers, 2017–2023 · strength 0.95
  4. Wen‐Ying Chen · 4 shared papers, 2017–2022 · strength 0.42
  5. Dandan Zheng · 2 shared papers, 2021–2024 · strength 0.40
  6. Sihua Lan · 2 shared papers, 2022–2023 · strength 0.38
  7. Liting Lu · 2 shared papers, 2021–2022 · strength 0.29
  8. Wa Zhong · 1 shared paper, 2023 · strength 0.22
  9. Sven‐Thorsten Liffers · 1 shared paper, 2026 · strength 0.20
  10. Diana Behrens · 1 shared paper, 2026 · strength 0.20
  11. Phyllis F. Cheung · 1 shared paper, 2026 · strength 0.20
  12. Marija Trajkovic‐Arsic · 1 shared paper, 2026 · strength 0.20
  13. Markus Vogt · 1 shared paper, 2026 · strength 0.20
  14. Elmar Wolf · 1 shared paper, 2026 · strength 0.20
  15. Barbara T. Grünwald · 1 shared paper, 2026 · strength 0.20
  16. Niklas Krebs · 1 shared paper, 2026 · strength 0.20
  17. Laura Godfrey · 1 shared paper, 2026 · strength 0.20
  18. Rita Teresa Lawlor · 1 shared paper, 2026 · strength 0.20
  19. Jens Thomas Siveke · 1 shared paper, 2026 · strength 0.20
  20. Rickmer Braren · 1 shared paper, 2026 · strength 0.20
  21. Aldo Scarpa Scarpa · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.